Simcha Blotnick
Jerusalem, JM, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Comparison of CYP2C9 activity between Ethiopian and non-Ethiopian Jews: an interethnic study of (S)-warfarin pharmacokinetic and pharmacodynamic.
Journal: Frontiers in pharmacology
Published: March 23, 2026
First-in-class intranasal epinephrine spray for anaphylaxis: Dose finding clinical study.
Journal: The journal of allergy and clinical immunology. Global
Published: December 30, 2024
A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: May 25, 2024
Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis.
Journal: The journal of allergy and clinical immunology. In practice
Published: November 23, 2022
Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Journal: Journal of translational medicine
Published: November 16, 2022
Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.
Journal: Clinical pharmacokinetics
Published: May 04, 2022
The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin.
Journal: European journal of clinical pharmacology
Published: July 19, 2018
The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex.
Journal: Pharmacogenetics and genomics
Published: May 17, 2018
Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.
Journal: Molecular diagnosis & therapy
Published: November 24, 2016
Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.
Journal: Pharmacogenetics and genomics
Published: August 28, 2015
The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals.
Journal: Pharmacogenetics and genomics
Published: November 02, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026